Barrington analyst Michael Petusky maintained a Buy rating on Opko Health (NASDAQ: OPK) today and set a price target of $7. The company’s shares opened today at $3.49.
Petusky said:
“We know that management received several questions regarding the recent news that the SEC has launched an investigation into the trading of certain low‐priced securities, and that CEO and Chairman Dr. Phil Frost and OPKO were among the investors whose activities are now under SEC review. The general thrust of the investigation seems to involve allegations of “pump and dump” stock trading. We simply do not have enough information to make any kind of high conviction call on the ultimate outcome of this investigation, but we can say that both Dr. Frost and OPKO have a long history of making investments in smaller companies. In the case of OPKO (and to the best of our knowledge), not a dollar of investment that the company has made in any of the trading activity being examined by the SEC has ever been monetized. Regarding Dr.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 14.2% and a 59.2% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and DENTSPLY SIRONA Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Opko Health with a $10.50 average price target.
See today’s analyst top recommended stocks >>
Based on Opko Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.2 million. In comparison, last year the company had a GAAP net loss of $46.44 million.
Based on the recent corporate insider activity of 95 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year. Most recently, in July 2018, Phillip Frost, the CEO & Chairman of OPK bought 90,000 shares for a total of $455,127.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations.
